Consensus Aligos Therapeutics, Inc.

Stocks

ALGS

US01626L2043

Biotechnology & Medical Research

Market Closed - Nasdaq 01:00:00 03/11/2026 +04			5-day change	1st Jan Change
4.600 ^USD	-4.17%		-1.08%	-50.64%

10-21	US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment	RE
08-13	Aligos Therapeutics Initiates Dosing in Phase 1 Study of Alg-170675 for Chronic Hepatitis B Virus Infection	CI

Evolution of the Average Target: Aligos Therapeutics, Inc.

Evolution of the Target Price: Aligos Therapeutics, Inc.

Changes in Analyst Recommendations: Aligos Therapeutics, Inc.

d5ad74.BdL4ZUQCEEq2Neg63z7iwHwUqUkVjQgr84FIR8d4IaY.SaiPFRdvUS_FA9pdtGrQpw4lm397x1hHwsQtDPENDPFzv58Vd11iIcV-jw~43ea66669d8d9430e52c1bf328f6dc93

Analysts' recommendations: Aligos Therapeutics, Inc.

05-28	Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target	MT
01-07	UBS Initiates Aligos Therapeutics at Buy With $20 Price Target	MT
19/08/24	HC Wainwright Initiates Aligos Therapeutics at Buy With $75 Price Target	MT
17/01/23	Piper Sandler Adjusts Price Target on Aligos Therapeutics to $7 From $3, Maintains Overweight Rating	MT
06/01/23	Piper Sandler Upgrades Aligos Therapeutics to Overweight From Neutral, Adjusts Price Target to $3 From $2	MT
06/01/23	Jefferies Upgrades Aligos Therapeutics to Buy From Hold, Adjusts Price Target to $3 From $2.50	MT
03/11/22	SVB Securities Adjusts Aligos Therapeutics' Price Target to $2 From $3, Keeps Market Perform Rating	MT
08/08/22	Cantor Fitzgerald Downgrades Aligos Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.20 From $11	MT
05/05/22	SVB Leerink Cuts Aligos Therapeutics to Market Perform From Outperform, Price Target to $3 From $7	MT
23/03/22	Jefferies Lowers Price Target for Aligos Therapeutics to $2.50 From $5, Maintains Hold Rating	MT
23/03/22	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $7 from $11, Keeps Outperform Rating	MT
23/03/22	Piper Sandler Cuts Aligos Therapeutics to Neutral From Overweight, Price Target to $4 From $15	MT
11/03/22	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $11 from $10, Keeps Outperform Rating	MT
16/02/22	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $10 from $15, Maintains Outperform Rating	MT
08/01/22	Jefferies Downgrades Aligos Therapeutics to Hold From Buy, Adjusts Price Target to $5 From $20	MT
07/01/22	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $15 from $29, Keeps Outperform Rating	MT
07/01/22	JPMorgan Lowers Aligos Therapeutics to Neutral From Overweight, Price Target to $12 From $30	MT
09/09/21	Aligos Therapeutics : SVB Leerink Starts Aligos Therapeutics at Outperform with $29 Price Target	MT
17/05/21	Aligos Therapeutics : Piper Sandler Initiates Coverage on Aligos Therapeutics With Overweight Rating, $47 Price Target	MT
24/03/21	Aligos Therapeutics : Piper Sandler Adjusts Price Target on Aligos Therapeutics to $40 From $35, Maintains Overweight Rating	MT
21/12/20	Aligos Therapeutics : Jefferies & Co Adjusts Aligos Therapeutics PT to $30 From $26, Maintains Buy Rating	MT
10/11/20	Aligos Therapeutics : Cantor Fitzgerald Starts Aligos Therapeutics at Overweight With $28 Price Target	MT
10/11/20	Aligos Therapeutics : Piper Sandler Starts Aligos Therapeutics at Overweight With $35 Price Target	MT
10/11/20	Aligos Therapeutics : JPMorgan Starts Aligos Therapeutics at Overweight With $33 Price Target	MT
10/11/20	Aligos Therapeutics : Jefferies & Co Initiates Coverage on Aligos Therapeutics With Buy Rating, $26 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALIGOS THERAPEUTICS, INC.					+1,038.59%
	WUXI APPTEC CO., LTD.					+45.94%
	ARGENX SE					+27.74%
	LONZA GROUP AG					+8.21%
	IQVIA HOLDINGS INC.					+20.68%
	BEONE MEDICINES AG					+21.12%
	REVOLUTION MEDICINES, INC.					+37.56%
	GENMAB A/S					+8.25%
	CELLTRION, INC.					+40.97%
	INSMED INCORPORATED					+77.27%
	Average					+132.63%
	Weighted average by Cap.					+30.02%